NeuroMetrix, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- NeuroMetrix Inc develops and commercializes non-invasive neurotechnology medical devices for diagnosing and treating chronic pain and neurological disorders including diabetic peripheral neuropathy; core products include Quell a wearable FDA-cleared drug-free neurostimulation device for chronic pain relief in legs feet and knees with app connectivity for therapy tracking used by consumers and clinicians and DPNCheck a point-of-care nerve conduction test for rapid non-invasive assessment of peripheral neuropathies targeted at endocrinologists podiatrists primary care physicians and managed care organizations. Founded in 1996 and headquartered in Woburn Massachusetts the company operates primarily in the United States with global commercialization efforts serving healthcare providers and patients seeking alternatives to pharmaceuticals. In 2025 electroCore Inc completed its acquisition of NeuroMetrix rendering it a wholly-owned subsidiary while NeuroMetrix continues to offer Quell under its brand enhancing electroCore's bioelectronic portfolio particularly for chronic pain solutions in the VA Hospital System and broadening market access for non-invasive therapies.
electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies
NEUROMETRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NeuroMetrix, Inc. - NURO
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of NeuroMetrix, Inc. - NURO
NURO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NeuroMetrix, Inc. Is Fair to Shareholders
electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness
NeuroMetrix to be Acquired by electroCore
NeuroMetrix Q3 Loss Narrows Y/Y, Quell Sales Drives Growth
NeuroMetrix Reiterates its Review of Strategic Alternatives
NeuroMetrix, Inc. (NURO) Q2 2024 Earnings Call Transcript
NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call
Head-To-Head Analysis: NeuroMetrix (NASDAQ:NURO) & Sharps Technology (NASDAQ:STSS)
NeuroMetrix Reports Q1 2024 Business Highlights
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired
Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.
NeuroMetrix, Inc. (NURO) Q4 2023 Earnings Call Transcript
NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call